Markets:

Overview

News

Currencies

International

Treasuries

PDS Biotechnology Corporation - Common Stock (NQ:PDSB)

0.7511 +0.0311 (+4.32%)

Streaming Delayed Price Updated: 2:07 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about PDS Biotechnology Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market ↗

November 13, 2025

PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

A Look Ahead: PDS Biotechnology's Earnings Forecast ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 11, 2025

Via Benzinga

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval ↗

October 30, 2025

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

Via Stocktwits

Insights into PDS Biotechnology's Upcoming Earnings ↗

August 12, 2025

Via Benzinga

Insights Ahead: PDS Biotechnology's Quarterly Earnings ↗

May 13, 2025

Via Benzinga

A Look at PDS Biotechnology's Upcoming Earnings Report ↗

March 26, 2025

Via Benzinga

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026 ↗

October 30, 2025

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Via Stocktwits

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress ↗

August 13, 2025

PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet.

Via Chartmill

PDSB Loss Improves as Costs Drop ↗

August 13, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

Uncovering Potential: PDS Biotechnology's Earnings Preview ↗

November 13, 2024

Via Benzinga

Earnings Preview For PDS Biotechnology ↗

March 26, 2024

Via Benzinga

Analyst Expectations for PDS Biotechnology's Future ↗

November 15, 2023

Via Benzinga

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

PDS Biotechnology: Q3 Earnings Insights ↗

November 14, 2023

Via Benzinga

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish ↗

March 27, 2025

The company said the reduced losses were primarily due to decreased operating expenses.

Via Stocktwits

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024 ↗

August 13, 2024

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024 ↗

May 15, 2024

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 27, 2024

Via Benzinga

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 ↗

March 27, 2024

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 27, 2024

Via Benzinga

Earnings Scheduled For March 27, 2024 ↗

March 27, 2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in March 2024 ↗

March 13, 2024

These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.